London, UK (PRWEB) October 25, 2013
To date, there is a vital necessity to create antibiotic therapies undermining resistance mechanisms in a more effective way. The number of new antibiotic approvals has declined by approximately 60% during the last decade. However, in the recent past, a broad range of novel approaches to antibiotic drug development have been introduced. Currently, there are more than 100 candidates in the pipeline, with many of them being new molecular classes targeting pathogens in new ways in comparison with the existing drugs.
Most of the 113 molecules in the pipeline are being developed by medium-sized and small companies, with only around 28% being developed by international corporations. Close to 70% of all marketed antibiotics belong within just 5 various classes, and the majority of these antibiotics have been used to treat a wide range of pathogens for a long period, which has led to the rates of antimicrobial resistance witnessed today.
Topical research report “Antibiotic Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance” worked out by Biopharm Reports has been recently published by Market Publishers Ltd.
Title: Antibiotic Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance
Published: February, 2013
Price: US$ 2,905.00
The report offers a comprehensive guide to the antibiotic R&D field. It covers 113 molecules in the pipeline, describes the competitive environment in the marketplace and reviews the top antibiotic development companies. The research study discusses the various strategies being progressed by developers to target antibiotic resistant bacterial strains (including targets, mechanisms, combinations and other areas), examines innovation activities and new product opportunities, as well as describes the current clinical practices in targeting the main bacterial pathogens.
- Extensive overview of the antibiotic R&D field.
- Comprehensive analysis of 113 molecules in the pipeline (including mechanisms, classes and combinations (Preclinical to Phase III), and clinical findings (Phase II, III)).
- Review of the leading companies involved in the development or marketing of antibiotics.
- Discussion of the main strategies adopted to target antibiotic resistance (including targets, mechanisms, combinations and other areas).
- Outlining of the major opportunities for innovation and new product development.
- Insightful overview of the current clinical practices in the targeting the main bacterial pathogens.
More in-demand research reports by the publisher can be found at Biopharm Reports page.